CureVac Announces U.S. Patent Grant for mRNA Vaccination of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
24
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV

Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition

TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that the U.S. Patent and Trademark Office (USPTO) has granted a fundamental patent for the use of mRNA encoding the Respiratory Syncytial Virus (RSV) F-protein for vaccination of infants up to two years of age (US Patent No. 10,172,935). The F-protein is the major antigen of RSV and forms the basis of potential future RSV vaccines. The USPTO already granted a similar patent in 2017 that relates to vaccination of infants for the prophylaxis of influenza. Moreover, similar patents have already been granted to CureVac in Europe and Japan. Together, these broad technology patents strengthen CureVac’s industry-leading position in the mRNA space as the Company develops preventative vaccine candidates for severe infectious diseases, such as RSV and influenza.

CureVac’s mRNA technology uses optimized mRNA encoding F-protein to stimulate a protective and balanced immune response against RSV. For such optimized mRNA constructs, CureVac already holds a U.S. patent that supplements CureVac’s patent portfolio regarding RSV vaccination.

Vaccination of infants is especially difficult because they do not yet have fully established immune systems. Several efforts in the industry to develop and market a prophylactic RSV vaccine have failed to date. Therefore, vaccination of infants against RSV remains an unmet need and one of the major challenges for prophylactic vaccination.

This patent strengthens CureVac’s broad IP portfolio, among the most comprehensive in the industry, with more than 110 patent families, over 1000 patent family members and more than 190 granted patents.

About RSV

RSV is a common respiratory virus and is the most common cause of bronchiolitis and pneumonia in children younger than one year of age in the U.S. An estimated 3.4 million children younger than five years of age are hospitalized each year with severe RSV lower respiratory tract infection, with the highest incidence in children younger than six months of age. RSV is second only to influenza as a cause of medically significant respiratory tract illnesses in adults and is estimated to cause 177,000 hospitalizations and 14,000 annual deaths in U.S. adults age 65 years and older. In the northern hemisphere and areas with similar climates, RSV infections occur primarily during fall, winter, and spring. 1

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG .

Media Contact

Jenn Gordon, Media Relations Global Health PR, New York, United States T: +1 202-587-2580 jgordon@globalhealthpr.com

Investor Contact

Matthew Beck, Vice President Investor Relations CureVac AG, Boston, MA, United States T: +1 917-415-1750 matthew.beck@curevac.com

1 “Respiratory Syncytial Virus Infection” Centers for Disease Control and Prevention. June 2018. Last Accessed January 2019. https://www.cdc.gov/rsv/index.html

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 46

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 52

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 42

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 16

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 0

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 23

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 229

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 48

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading

Top 5 Most Recently Viewed Articles

Liberty Media Corp Achieves Milestone with Stock Surge

Updated Category News Views 203

Liberty Media Corporation Reaches New 52-Week High Liberty Media Corp (FWONA), a significant player in the media and entertainment sectors, has recently achieved a landmark 52-week high in its stock price, soaring to $75.71. This impressive rise has brought attention to the company's strong market performance, reflecting a substantial gain of 31.03% over the past year....

Continue Reading
Telegram's Pavel Durov Responds to Content Moderation Criticism

Updated Category News Views 200

Pavel Durov Addresses Concerns Over Telegram's Moderation Pavel Durov, the CEO of Telegram, has recently addressed the growing concerns about the platform’s moderation practices. In a message to his large audience of over 12 million subscribers, Durov pledged that the company would take steps to respond to the criticism regarding how Telegram handles content management....

Continue Reading
FiscalNote Expands Its Reach with New Public Sector Customers

Updated Category News Views 107

FiscalNote Expands Its Reach with New Public Sector Customers FiscalNote Holdings, Inc. (NYSE: NOTE), renowned for its AI-driven enterprise SaaS technologies, has recently made headlines by securing a myriad of new agreements across the U.S. public sector. These contracts span the federal government's three branches, showcasing the Company's celebrated suite of products...

Continue Reading
Bluejay Diagnostics to Showcase Symphony IL-6 Findings at SAEM

Updated Category News Views 117

Exciting Announcement from Bluejay Diagnostics Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has recently made a remarkable announcement that will resonate within the medical community. This innovative healthcare company has had an abstract accepted for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting. This significant event is scheduled to take...

Continue Reading
Clean Maine Carbon Launches Biochar Carbon Credits Through Puro.earth

Updated Category News Views 334

Clean Maine Carbon's Groundbreaking Initiative Clean Maine Carbon (CMC) has taken a significant step forward in sustainable carbon removal by launching its first biochar CO2 Removal Certificates (CORCs). Teaming up with Flowcarbon as its carbon development partner, CMC's move marks a pivotal moment in the quest for innovative solutions to combat climate change. The Role...

Continue Reading